Search - tctmd.com

Displaying 41 - 60 of 654

Sort: Relevancy | Date

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

News Conference News ESC 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

September 04, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

COVID-19 Vaccination Tied to Fewer CV Events in Large UK Study

News Daily News

COVID-19 Vaccination Tied to Fewer CV Events in Large UK Study

August 01, 2024

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

News Conference News SCCT 2024

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

July 25, 2024

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Industry News

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

May 29, 2024

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

One in Three Overweight MI Patients May Benefit From Semaglutide

News Daily News

One in Three Overweight MI Patients May Benefit From Semaglutide

February 26, 2024

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

News Daily News

TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable

Michael O'Riordan

January 09, 2024

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Top Coronary Artery Disease News of 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

News Daily News

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

Michael O'Riordan

November 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.